1. My research interest is focussed on understanding the molecular and immunological mechanisms of Inborn Errors of Immunity with a view to the rational design of smart therapies for these rare disorders. My research team investigates the role of the NF kappa B signalling pathway in antibody deficiency, undertakes functional validation of variants of unknown significance (VUS) and characterises the immunological heterogeneity of Common Variable Immunodeficiency (CVID). I am also interested in the rational design of novel immunotherapies, e.g. a genetically engineered chimaeric protein of HLA-G fused with a targeting moiety that specifically inhibits allogeneic graft rejection (patent granted in many world regions).

1. Dr Ibrahim trained as a physician and scientist in Immunology at University College London and Imperial College Schools of Medicine, before joining King’s in 2001. Since then he has created two new outpatient-based clinical allergy and primary immunodeficiency (PID) services for adults. The PID service sees patients from across south east England. He is Director of King’s Health Partners (KHP) Diagnostic Immunology Laboratory and has overseen expansion and improvements since taking up this role in 2004.

Dr Ibrahim's strategic programme of research aims to use his knowledge of immunology and dendritic cells to design rational and novel immunotherapies. His clinical and scientific expertise is recognised nationally and internationally - he has lectured and delivered research presentations internationally, and he reviews submissions to journals and grants for national and international bodies.